Histiocytosis is a general name for a group of disorders or "syndromes" that involve an abnormal increase in the number of specialized white blood cells that are called histiocytes.
Recently, new knowledge about this family of diseases has led experts to develop a new classification. Five categories have been proposed:
L group -- includes Langerhans cell histiocytosis and Erdheim-Chester disease
C group -- includes non-Langerhans cell histiocytosis that involves the skin
M group -- includes malignant histiocytosis
R group -- includes Rosai-Dorfman disease
H Group -- includes hemophagocytic lymphohistiocytosis
This article focuses only on the L group, which includes Langerhans cell histiocytosis and Erdheim-Chester disease.
There has been debate as to whether Langerhans cell histiocytosis and Erdheim-Chester disease are inflammatory, immune disorders, or cancer-like conditions. Recently, through the use of genomics scientists have found that these forms of histiocytosis show gene changes (mutations) in early white blood cells. This leads to abnormal behavior in the cells. The abnormal cells then increase in various parts of body including the bones, skin, lungs, and other areas.
Langerhans cell histiocytosis is a rare disorder that can affect people of all ages. The highest rate is among children ages 5 to 10. Some forms of the disorder are genetic, which means they are inherited.
Erdheim-Chester disease is a rare form of histiocytosis affecting mainly adults that involves multiple parts of the body.
Symptoms
Both Langerhans cell histiocytosis and Erdheim-Chester disease can affect the whole body (systemic disorder).
Symptoms can vary between children and adults, but they may have some of the same symptoms. Tumors in weight-bearing bones, such as the legs or spine, may cause the bones to fracture without an obvious reason.
There are no specific blood tests for Langerhans cell histiocytosis or Erdheim-Chester disease. The tumors produce a "punched-out" look on a bone x-ray. Specific tests vary, depending on the age of the person.
Blood and tissue testing for gene mutations including BRAF V600E. This testing may need to be done at a specialized center.
Langerhans cell histiocytosis is sometimes linked to cancer. CT scans and biopsy should be done to rule out possible cancer.
Treatment
People with Langerhans cell histiocytosis that involves only a single area (such as bone or skin) may be treated with local surgery. However, they will need to be followed closely to look for signs that the disease has spread.
People with widespread Langerhans cell histiocytosis or Erdheim-Chester disease require medicines to reduce symptoms and control the spread of the disease. Recent studies show that nearly all adults with widespread histiocytosis have gene mutations in the tumors, which appear to cause the disorder. Medicines that inhibit these gene mutations, such as vemurafenib are currently available. Other similar drugs are also in development.
Langerhans cell histiocytosis and Erdheim-Chester disease are very rare disorders. Therefore there is limited information about the best course of treatment. People with these conditions may want to take part in ongoing clinical trials designed to identify new treatments.
Other medicines or treatments may be used, depending on the outlook (prognosis) and response to the starting medicines. Such treatments may include:
Interferon alpha
Cyclophosphamide or vinblastine
Etoposide
Methotrexate
Vemurafenib, if the BRAF V600E mutation is found
Stem cell transplantation
Other treatments may include:
Antibiotics to fight infections
Breathing support (with a breathing machine)
Hormone replacement therapy
Physical therapy
Special shampoos for scalp problems
Supportive care (also called comfort care) to relieve symptoms
In addition, people with these conditions who smoke are encouraged to stop since smoking may worsen the response to treatment.
Support Groups
Histiocytosis Association --
Outlook (Prognosis)
Langerhans cell histiocytosis and Erdheim-Chester disease can affect many organs and can lead to death.
About one half of those with pulmonary histiocytosis improve, while others have permanent loss of lung function over time.
In very young people, the outlook depends on the specific histiocytosis and how severe it is. Some children can live a normal life with minimal disease involvement, while others do poorly. Young children, especially infants, are more likely to have body-wide symptoms that lead to death.
Problems with the pituitary gland that lead to growth failure
When to Contact a Medical Professional
Contact your health care provider if you or your child has symptoms of this disorder. Go to the emergency room if shortness of breath or chest pain develops.
Prevention
Avoid smoking. Quitting smoking can improve the outcome in people with Langerhans cell histiocytosis that affects the lungs.
Goyal G, Young JR, Koster MJ, et al. The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. 2019;94(10):2054-2071. PMID: 31472931 .
Rollins BJ, Berliner N. Histiocytoses. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 160.
Last reviewed May 9, 2024 by Neil J. Gonter, MD, Assistant Professor of Medicine, Columbia University, NY and private practice specializing in Rheumatology at Rheumatology Associates of North Jersey, Teaneck, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team..
BOB体育 research scientists make medicine better every day. They discover new ways to help
people by running clinical trials. When you join a clinical trial, you can get advanced
medical care. Sometimes years before it's available everywhere. You can also help make
medicine better for everyone else.
If you'd like to learn more about clinical trials, visit our
clinical trials page. Or click one of the links below:
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after鈥�